JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, S. H.
Right arrow Articles by Zonnenberg, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, S. H.
Right arrow Articles by Zonnenberg, B. A.

The Placorhen Study: A Double-Blind, Placebo-Controlled, Randomized Radionuclide Study with 186Re-Etidronate in Hormone-Resistant Prostate Cancer Patients with Painful Bone Metastases

Shiuw H. Han, MD, PhD1, John M.H. de Klerk, MD, PhD1, Suzy Tan, MSc1, Alfred D. van het Schip, PhD1, Bert H. Derksen1, Aalt van Dijk, PharmD1, Cas L.J.J. Kruitwagen, MSc2, Geert H. Blijham, MD, PhD3, Peter P. van Rijk, MD, PhD1 and Bernard A. Zonnenberg, MD, PhD3

1 Department of Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands
2 Center for Biostatistics, University of Utrecht, Utrecht, The Netherlands
3 Oncology Section, Department of Internal Medicine, University Medical Center Utrecht, Utrecht, The Netherlands



View larger version (63K):

[in a new window]
  		FIGURE 1. Scintigraphy of prostate cancer patient with multiple bone metastases.

 


View larger version (115K):

[in a new window]
  		FIGURE 2. Electronic palm-top computer diary (personal digital assistant).

 


View larger version (25K):

[in a new window]
  		FIGURE 3. Placorhen study flowchart of randomized patients in placebo and rhenium groups.

 


View larger version (18K):

[in a new window]
  		FIGURE 4. Change in visual analog score (A), medication index (B), and daily activity (C) in placebo group and rhenium group during follow-up. VAS = visual analog score; 0 = time at baseline.

 


View larger version (24K):

[in a new window]
  		FIGURE 5. Distribution of patients in relation to therapy and number of response days.

 


View larger version (20K):

[in a new window]
  		FIGURE 6. Kaplan-Meier curves of treatment groups in relation to time to request for radiotherapy.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.